China Biologic Awarded CFDA Approval to Manufacture Plasma Product

China Biologic Products, a Beijing-based plasma company, received CFDA approval to begin commercial manufacturing of human prothrombin complex concentrate (PCC) at its Shandong Taibang facility. For China Biologic, PCC represents new revenue from plasma that would otherwise be discarded. China Biologic, which expects to receive a GMP certificate for the facility before year-end, will also produce PCC from its recently completed Guizhou Taibang facility. More details.... Stock Symbol: (NSDQ: CBPO) Share this with colleagues: // //